Precision Health Outcomes: From Data to Targeted Disease Solutions

Cancer and chronic diseases are not isolated phenomena; they result from intricate interactions between genetic predispositions and environmental exposures. Understanding these interactions is pivotal for transforming public health strategies into precision interventions.

Defining Health Outcomes Architecture

Health outcomes architecture refers to the systematic design and integration of data, analytics, and clinical frameworks to measure, predict, and improve health outcomes across populations. This approach leverages multi-layered epidemiological and patient data to inform targeted interventions, optimize care delivery, and ultimately enhance patient and population health. It encompasses not just the physical spaces where care occurs, but also the digital and organizational structures that support evidence-based decision-making.

The Urgency: Chronic Disease Prevalence and Impact

Chronic diseases represent a staggering and growing threat to public health. In the United States alone, nearly 60% of adults live with at least one chronic disease, and about 40% have multiple chronic conditions. These illnesses—such as heart disease, cancer, and diabetes—are the leading causes of death and disability, accounting for approximately 90% of the nation’s $4.5 trillion annual healthcare expenditures. Globally, noncommunicable diseases are responsible for 74% of all deaths, with cardiovascular diseases and cancer leading the toll. This burden is projected to rise as the population ages, with the majority of adults over 50 expected to have at least one chronic disease by 2050.

As a leader in health outcomes architecture, Rubix LS is at the forefront of translating multi-layered epidemiological data into actionable therapeutic advancements. By harnessing the power of precision health frameworks, Rubix LS is driving the shift from broad public health approaches to targeted, data-driven solutions that address the complex realities of chronic disease.

The Bridge Between Data and Actionable Health Outcomes

Traditional public health methods have historically relied on broad-spectrum interventions—such as mass media campaigns or population-wide policies—that aim to shift health behaviors or exposures across entire populations without accounting for individual variability. While these approaches have achieved notable successes, they often fall short in addressing the unique risk profiles of individuals or high-risk subgroups. For example, population-level interventions like smoking bans have reduced overall smoking rates, but social inequities in smoking have actually widened, with disadvantaged groups benefiting less due to persistent social and economic barriers. Similarly, large-scale programs such as UNICEF's Accelerated Child Survival and Development initiative did not achieve better child survival outcomes in targeted areas, partly because broad interventions failed to address local implementation challenges and individual risk factors.

A key limitation of these traditional methods is their inability to integrate complex, multi-dimensional data—such as genetic predispositions, environmental exposures, and social determinants—into targeted, actionable strategies. As a result, health inequities persist, and interventions may not reach or benefit the most vulnerable populations.

Rubix LS’s approach represents a paradigm shift by leveraging health outcomes architecture to bridge this gap. By integrating environmental epidemiology with genomic insights, Rubix LS translates large-scale, multi-layered data into precise, tailored interventions for high-risk populations. This precision health model goes beyond treating existing diseases; it predicts and prevents disease by identifying those most at risk and designing interventions that are both data-driven and context-specific. For instance, Rubix LS’s SABRE Sight solution has been applied to develop and optimize diagnostic healthcare products, ensuring regulatory compliance, technical validation, and post-market surveillance—all informed by real-world evidence and continuous data analytics.

This approach not only enhances the effectiveness of interventions but also addresses the root causes of health inequities by considering the full spectrum of genetic, environmental, and social factors. In doing so, Rubix LS is redefining how data is translated into actionable health outcomes, moving from broad, one-size-fits-all strategies to targeted, impactful solutions that improve both individual and population health.

Key Innovations Driving This Shift:

• Multi-Omics Integration: By combining genomic, transcriptomic, and environmental data, multi-omics integration enables the identification of precise biomarkers and exposure pathways linked to disease progression. This innovation allows clinicians and researchers to deeply phenotype individuals, facilitating earlier detection and more targeted interventions. For patients, this means more personalized care and the potential to prevent disease before symptoms arise. For public health initiatives, multi-omics integration empowers the development of population-specific strategies that address the root causes of chronic diseases, rather than relying on a one-size-fits-all approach.

• AI-Driven Risk Stratification: Artificial intelligence and machine learning models analyze vast, longitudinal datasets, including electronic health records, genetic information, and real-time health metrics—to predict individual susceptibility to disease and likely treatment efficacy. This approach dramatically improves treatment timelines by enabling early detection of high-risk patients, allowing for prompt intervention and reducing the likelihood of adverse events. Research shows that healthcare organizations using AI-driven risk stratification have achieved a 25% improvement in early intervention outcomes, a 45% reduction in adverse events among high-risk patients, and a 35% reduction in emergency department visits. For patients, this means faster, more accurate diagnoses and better health outcomes; for public health, it translates to more efficient resource allocation and reduced healthcare costs.

• Policy-Driven Infrastructure: Collaborating with policymakers to embed genomic and environmental data into public health frameworks ensures that precision health innovations are scalable and equitable. By integrating these data streams into policy, public health initiatives can move beyond reactive care and toward proactive, preventive strategies. This approach supports the translation of cutting-edge research, such as polygenic risk scores, into actionable public health benefits, while also addressing ethical and equity considerations.

Together, these innovations are redefining the landscape of precision health. Multi-omics integration provides a comprehensive understanding of disease mechanisms, AI-driven risk stratification accelerates early detection and intervention, and policy-driven infrastructure ensures these advances benefit entire populations. As documented in leading research journals, these approaches are not only improving individual patient outcomes but are also transforming public health by enabling more targeted, effective, and equitable interventions.

Case Study: Breast Cancer and Environmental Risks

Breast cancer is one of the most prevalent cancers globally, with risk factors extending far beyond genetics. Environmental exposures, such as air pollution, endocrine-disrupting chemicals (EDCs), and socioeconomic disparities, significantly contribute to increasing incidence rates. To illustrate the tangible impact of these risks, consider the story of Maria, a 45-year-old woman living in an urban area with high levels of air pollution.

Maria's Story

Maria has always been diligent about her health, maintaining a balanced diet and regular exercise routine. However, she lives in a neighborhood with poor air quality, where she is frequently exposed to pollutants like nitrogen dioxide (NO2) and particulate matter. Research has shown that such exposure can increase the risk of breast cancer, particularly postmenopausal breast cancer, by affecting biological aging and DNA methylation patterns. Additionally, Maria's socioeconomic status limits her access to healthcare services, further exacerbating her risk due to delayed screenings and interventions.

Environmental Risks and Breast Cancer

Studies have consistently highlighted the role of environmental factors in breast cancer development. For instance, exposure to air pollutants like lead, mercury, and cadmium has been linked to an increased risk of postmenopausal breast cancer. Moreover, endocrine-disrupting chemicals found in plastics and personal care products have raised concerns due to their estrogen-like properties, although more research is needed to establish a clear link. The Environmental Quality Index (EQI) has also shown that poor environmental quality is associated with higher breast cancer incidence rates, particularly for localized and in situ cancers.

Research and Implications

Research journals have extensively documented the impact of environmental factors on breast cancer risk. For example, the Sister Study has provided valuable insights into how physical activity can reduce breast cancer risk, while also highlighting the dangers of air pollution. The Breast Cancer and the Environment Research Program (BCERP) further emphasizes the need to understand how environmental exposures interact with genetic predispositions to influence breast cancer development. Understanding these interactions is crucial for developing targeted interventions that address both individual and population-level risks.

By integrating these findings into public health strategies, we can move toward more effective prevention and treatment approaches that consider the complex interplay between genetics, environment, and socioeconomic factors. This holistic approach not only benefits individuals like Maria but also contributes to reducing the global burden of breast cancer.

Rubix LS and TheraSyn Bio (TSB) Collaboration:

Rubix LS and TSB are currently in the preclinical development stage of their joint project, known as Project Panacea, which aims to create a topical therapy for breast cancer. This early-stage research focuses on evaluating the safety, efficacy, and feasibility of the bioengineered treatment, with the goal of progressing toward clinical trials in the future.

Impact:

• Localized, Non-Invasive Treatment: Addresses disparities in access to traditional therapies, particularly benefiting underserved communities, by offering a targeted, minimally invasive option.

• Community-Centric Design: Combines clinical efficacy with environmental justice, ensuring solutions are tailored to regional health needs and environmental risks.

Applying Genomics to Rare and Aggressive Cancers

While common cancers receive significant research attention, rare and aggressive cancers, such as triple-negative breast cancer (TNBC) and sarcomas, require targeted approaches. The field faces substantial barriers to progress, particularly in genomic research. Limited patient populations make it difficult to collect statistically significant sample sizes, with rare cancers accounting for up to 25% of all cancer cases despite their individual rarity. Additionally, funding challenges persist as research dollars often flow toward more common cancers with larger patient advocacy groups. Access to comprehensive genomic testing remains inconsistent across geographic regions and populations, creating disparities in diagnosis and treatment opportunities.

Rubix LS employs advanced genomic sequencing combined with real-world environmental data to:

• Identify Genetic Markers: Pinpoint mutations or epigenetic changes linked to high-risk populations. This approach has shown significant promise, as comprehensive genomic and transcriptomic analysis has demonstrated clinical benefit in a substantial proportion of patients with advanced rare cancers. By identifying specific biomarkers, targeted therapies can be developed that dramatically improve patient outcomes compared to traditional approaches.

• Uncover Environmental Triggers: Analyze pollutants (e.g., particulate matter, industrial chemicals) that accelerate tumor progression. This integration of environmental factors with genomic data provides crucial context for understanding cancer development, especially in populations with higher exposure to carcinogens.

• Develop AI-Driven Models: Predict how genetic and environmental factors interact to influence treatment response. These models help overcome the statistical challenges inherent in rare cancer research by identifying patterns across multiple data types that might otherwise be missed in small sample sizes.

  
  

Focus on Underserved Groups

Rubix LS prioritizes populations disproportionately affected by these cancers, ensuring therapies are tailored to their unique risk profiles. This focus is essential because underserved communities often bear a disproportionate burden of both environmental exposures and barriers to healthcare access. Research has shown that up to 80% of rare cancer patients are treated at hospitals where genomic testing is not the standard of care, forcing patients to advocate for themselves individually. This creates significant gaps in care based on education, advocacy skills, financial resources, and other factors that contribute to healthcare inequities.

By specifically targeting these populations, Rubix LS addresses a critical gap in the current research landscape. Their approach acknowledges that cancer is not merely a biological phenomenon but is shaped by social determinants of health, environmental justice issues, and systemic barriers to care. This equity-focused strategy aims to ensure that advances in precision medicine benefit all patients, not just those with greater resources or access to specialized cancer centers.

Recent research published in journals such as Cancer Discovery and the Journal of Clinical Oncology has demonstrated that molecularly informed treatments can lead to clinical benefit in 35.7% of patients with advanced rare cancers, highlighting the importance of comprehensive genomic approaches in these underserved patient populations.

Expanding Access to Advanced Interventions

Precision health must be inclusive to be effective. Communities facing the highest environmental risks—such as industrial pollution or inadequate healthcare infrastructure—are often excluded from the latest genomic medicine advancements.

Rubix LS is addressing this gap by:

• Predictive Health Indices: These tools work by integrating individual and community-level data—including socioeconomic status, environmental exposures, and health records—to assess disease vulnerability. In practice, predictive health indices use algorithms and machine learning models to analyze trends and forecast health risks. For example, in a community with contaminated water sources, a predictive index might flag elevated cancer risks by combining local pollution data with health records and demographic information. This enables targeted screening and timely preventive measures, ensuring resources are allocated where they are needed most.

• Policy Partnerships: By collaborating with policymakers, Rubix LS helps deploy data-driven interventions in high-risk regions. This approach ensures that public health resources and preventive programs are guided by real-time, evidence-based insights, improving health equity and outcomes.

• Decentralized Clinical Trials: Expanding access to therapies—such as the breast cancer topical treatment—through community-based trials allows underserved populations to participate in cutting-edge research, accelerating the adoption of new interventions and reducing health disparities.

Example in Practice:

In Los Angeles County, researchers used predictive models to map neighborhoods at greatest risk for COVID-19 by evaluating barriers to healthcare, socioeconomic challenges, and environmental factors. This allowed public health officials to prioritize vulnerable populations for vaccination and preventive outreach, demonstrating how predictive health indices can drive real-world impact3.

Predictive analytics and health indices are rapidly transforming healthcare by enabling early disease detection, improving care coordination, and optimizing resource allocation. To explore the latest research and applications in this field, readers are encouraged to consult journals such as the American Journal of Preventive Medicine, Nature, and the International Journal of Environmental Health, which regularly publish studies on predictive analytics and population health management.

The Future of Health Outcomes Architecture

Rubix LS envisions a future where precision health fundamentally reshapes disease prevention and treatment through innovative, data-driven models. However, the current landscape is marked by persistent challenges: delayed detection of high-risk individuals, rigid treatment protocols that overlook environmental influences, and fragmented data systems that hinder effective public health responses. Many patients still experience late diagnoses, suboptimal therapies, and inequitable access to advanced interventions—especially in communities facing environmental and socioeconomic disadvantages.

How Rubix LS Is Addressing These Challenges

• AI-Powered Risk Stratification: Rubix LS is developing integrated platforms that combine genomic, environmental, and clinical data to identify high-risk individuals earlier and more accurately. These dynamic risk models adapt in real time to evolving exposure patterns, such as those driven by climate change, enabling proactive intervention and reducing preventable disease burden.

• Therapeutic Precision: By tailoring treatments to account for how environmental exposures influence drug efficacy, Rubix LS is advancing personalized dosing regimens based on each patient’s unique genetic and environmental profile. This precision reduces adverse effects and improves outcomes, especially for those most vulnerable to environmental risks.

• Policy Integration: Rubix LS collaborates with policymakers to embed genomic and environmental data into public health decision-making. This drives earlier, more effective interventions and supports the development of regulatory frameworks that enable decentralized, equitable care delivery.

Vision for the Next Decade

Looking ahead, Rubix LS aims to close the gap between scientific innovation and real-world impact. By 2030, the company’s goal is to enable every high-risk community to benefit from early disease detection, targeted therapies, and data-driven public health strategies—regardless of geography or socioeconomic status. This long-term vision is rooted in building resilient health systems that anticipate and prevent disease, rather than simply reacting to it.

Take the Next Step: Explore Our Impact

To learn more about Rubix LS’s commitment to sustainable, equitable health innovation—and to see how these efforts are measured and reported—read the Sustainability & Impact Report. This report provides a transparent overview of Rubix LS’s progress, challenges, and future milestones across environmental, social, and governance (ESG) dimensions, highlighting the company’s dedication to responsible, transformative health solutions.

Driving the Next Era of Precision Health with Rubix LS

Precision health demands an interdisciplinary approach that merges genomics, environmental science, and policy innovation. The urgency of this transformation cannot be overstated, studies show that delays in adopting precision medicine approaches significantly impact patient outcomes, with every day of avoidable access delay to precision health innovations in cancer care adding to years of potential life lost. In Europe alone, the time to market for precision therapies targeting EGFR mutations averages 469 days—significantly longer than for standard treatments, representing countless missed opportunities to improve patient survival.

Healthcare organizations recognize this urgency, with 49% already reporting that precision medicine positively impacts patient volume today, and 53% expecting this impact to grow within two years. Despite this recognition, implementation barriers persist, particularly for rare diseases where patients often endure years-long "diagnostic odysseys" before receiving appropriate care.

Rubix LS is leading this movement by ensuring that precision medicine evolves from concept to reality, accessible for all. By prioritizing conditions where precision approaches can make the greatest impact, including diabetes (targeted by 45% of healthcare organizations), common cancers (38%), and neurological diseases (33%), Rubix LS is addressing the most pressing healthcare challenges of our time.

By translating complex datasets into targeted solutions, Rubix LS is redefining healthcare delivery. The company's approach integrates the technologies identified as essential for precision medicine implementation: big data capture and storage, collaboration tools, predictive analytics, and decision support systems. This comprehensive strategy ensures that precision health benefits reach all patients, regardless of geography or socioeconomic status.

The future of medicine will be personalized, predictive, and equitable, ushering in a new era where no patient or community is left behind. As precision medicine continues to demonstrate positive impacts on drug discovery and treatment development, with 38% of healthcare organizations already seeing benefits today, Rubix LS is positioned at the forefront of this healthcare revolution.

Learn More About What We Do